Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on October 28, 2020, to report its financial results for the quarter ended September 30, 2020. The filing primarily directs investors to the accompanying press release (Exhibit 99.1) for detailed financial information, including both GAAP and non-GAAP metrics. Management believes non-GAAP measures offer useful insights for investors for operational and planning purposes, though they are not a substitute for GAAP-reported results and may differ from industry peers. Investors are encouraged to review the reconciliation provided in the press release for a comprehensive understanding of the financial performance. The core purpose of this 8-K is to formally disclose the third-quarter financial performance. While the 8-K itself is brief, the attached press release contains the substance of Gilead's operational and financial condition for the period. Investors should focus on the financial data and management commentary within Exhibit 99.1 to assess the company's performance, revenue drivers, profitability, and outlook.
Key Highlights
- 1Gilead Sciences announced its financial results for the quarter ended September 30, 2020, via an 8-K filing on October 28, 2020.
- 2The filing includes a press release (Exhibit 99.1) containing detailed financial information.
- 3Both GAAP and non-GAAP financial measures are presented.
- 4Management considers non-GAAP financial information useful for internal operational, budgeting, and financial planning purposes.
- 5Investors are advised that non-GAAP measures may be defined and calculated differently by other companies.
- 6A reconciliation between GAAP and non-GAAP financial information is available on pages 14-16 of the press release.
- 7The information provided is not deemed 'filed' for Section 18 of the Exchange Act.